Alpha Cubed Investments LLC Acquires 17,708 Shares of Zoetis Inc. (NYSE:ZTS)

Alpha Cubed Investments LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 118,162 shares of the company’s stock after acquiring an additional 17,708 shares during the quarter. Zoetis accounts for 1.3% of Alpha Cubed Investments LLC’s portfolio, making the stock its 26th largest position. Alpha Cubed Investments LLC’s holdings in Zoetis were worth $23,322,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after acquiring an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its holdings in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Ramirez Asset Management Inc. bought a new stake in shares of Zoetis in the 3rd quarter worth about $35,000. First Financial Corp IN lifted its holdings in shares of Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after acquiring an additional 79 shares during the last quarter. Finally, FinTrust Capital Advisors LLC lifted its holdings in shares of Zoetis by 42.1% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock worth $45,000 after acquiring an additional 77 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.3 %

Shares of NYSE:ZTS traded down $0.53 during trading on Tuesday, reaching $159.17. The stock had a trading volume of 3,647,859 shares, compared to its average volume of 3,147,432. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a market capitalization of $72.80 billion, a P/E ratio of 31.60, a PEG ratio of 2.42 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm’s 50-day simple moving average is $171.21 and its 200 day simple moving average is $179.23.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $1.15 earnings per share. As a group, research analysts expect that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 2,209 shares of company stock worth $371,293 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. The Goldman Sachs Group raised their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays reduced their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Stifel Nicolaus reduced their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $216.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.